Skip to main content
SpringerLink
Log in

Superior Efficacy of Infliximab Versus Adalimumab for First-Line Treatment of Crohn’s Perianal Fistulae

  • Original Article
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Background

Crohn’s disease perianal fistulae (CD-PAF) occur in 25% of patients and are notoriously challenging to manage. Tumor necrosis factor inhibitors are first line agents.

Aims

The aim of this study was to compare infliximab (IFX) versus adalimumab (ADA) efficacy in CD-PAF healing over time.

Methods

A retrospective study at two large-tertiary medical centers was performed. Inclusion criteria were actively draining CD-PAF and initial treatment with IFX or ADA following CD-PAF diagnosis. The primary endpoints were perianal fistula response and remission at 6 and 12 months. Secondary endpoints included biologic persistence over time and dose escalation at 6 and 12 months.

Results

Among 151 patients included in the study, 92 received IFX and 59 received ADA as first line agents after CD-PAF diagnosis. At 6 months, the 64.9% of the IFX group and 34.8% of the ADA group demonstrated CD-PAF clinical improvement (p < 0.01). Univariate and multivariate analyses demonstrated significant differences among the IFX and ADA groups for clinical response at 6-months and 12-months (p = 0.002 and p = 0.042, respectively). There were no factors that predicted response, with the exception of concomitant immunomodulator affecting the 6-month clinical response (p = 0.021). Biologic persistence, characterized by Kaplan Meier methods, was significantly longer in the IFX group compared to the ADA group (Log-rank p = 0.01).

Conclusion

IFX induction and maintenance is associated with higher rates of response and remission in CD-PAF healing as well as higher treatment persistence compared to ADA. Additionally, our study supports the use of concomitant immunomodulator therapy for CD-PAF healing and remission.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Mak WY, Mak OS, Lee CK et al. Significant medical and surgical morbidity in perianal Crohn’s disease: results from a territory-wide study. J. Crohn’s Colitis. 2018;12:1392–1398.

    Article  Google Scholar 

  2. Panes J, Reinisch W, Rupniewska E et al. Burden and outcomes for complex perianal fistulas in Crohn’s disease: systematic review. World J. Gastroenterol. 2018;24:4821–4834.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Yarur AJ, Kanagala V, Stein DJ et al. Higher infliximab trough levels are associated with perianal fistula healing in patients with Crohn’s disease. Aliment. Pharmacol. Ther. 2017;45:933–940.

    Article  CAS  PubMed  Google Scholar 

  4. Schwartz DA, Loftus EV, Tremaine WJ et al. The natural history of fistulizing Crohn’s disease in Olmsted County, Minnesota. Gastroenterology. 2002;122:875–880.

    Article  PubMed  Google Scholar 

  5. Adegbola SO, Dibley L, Sahnan K et al. Burden of disease and adaptation to life in patients with Crohn’s perianal fistula: a qualitative exploration. Health Qual Life Outcomes. 2020;18:370.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Vasudevan A, Bruining DH, Loftus EV, Faubion W, Ehman EC, Raffals L. Approach to medical therapy in perianal Crohn’s disease. World J. Gastroenterol. 2021;27:3693–3704.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Present DH, Rutgeerts P, Targan S et al. Infliximab for the treatment of fistulas in patients with Crohn’s disease. N. Engl. J. Med. 1999;340:1398–1405.

    Article  CAS  PubMed  Google Scholar 

  8. Colombel J-F, Schwartz DA, Sandborn WJ et al. Adalimumab for the treatment of fistulas in patients with Crohn’s disease. Gut. 2009;58:940–948.

    Article  CAS  PubMed  Google Scholar 

  9. Hanauer SB, Sandborn WJ, Rutgeerts P et al. Human anti-tumor necrosis factor monoclonal antibody (Adalimumab) in crohn’s disease: the CLASSIC-I Trial. Gastroenterology. 2006;130:323–333.

    Article  CAS  PubMed  Google Scholar 

  10. Sandborn WJ, Rutgeerts P, Enns R et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann. Intern. Med. 2007;146:829–838.

    Article  PubMed  Google Scholar 

  11. Singh S, Proctor D, Scott FI, Falck-Ytter Y, Feuerstein JD. AGA technical review on the medical management of moderate to severe luminal and perianal fistulizing Crohn’s disease. Gastroenterology. 2021;160:2512-2556.e2519.

    Article  PubMed  Google Scholar 

  12. Sandborn WJ, Fazio VW, Feagan BG, Hanauer SB. AGA technical review on perianal Crohn’s disease. Gastroenterology. 2003;125:1508–1530.

    Article  PubMed  Google Scholar 

  13. Ji C-C, Takano S. Clinical efficacy of adalimumab versus infliximab and the factors associated with recurrence or aggravation during treatment of anal fistulas in Crohn’s disease. Intest Res 2017;15:182–186.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Gisbert JP, Marín AC, McNicholl AG, Chaparro M. Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed. Aliment. Pharmacol. Ther. 2015;41:613–623.

    Article  CAS  PubMed  Google Scholar 

  15. Taxonera C, Schwartz DA, García-Olmo D. Emerging treatments for complex perianal fistula in Crohn’s disease. World J. Gastroenterol. 2009;15:4263–4272.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Sands BE, Anderson FH, Bernstein CN et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N. Engl. J. Med. 2004;350:876–885.

    Article  CAS  PubMed  Google Scholar 

  17. Colombel JF, Sandborn WJ, Rutgeerts P et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology. 2007;132:52–65.

    Article  CAS  PubMed  Google Scholar 

  18. Castaño-Milla C, Chaparro M, Saro C et al. Effectiveness of adalimumab in perianal fistulas in crohn’s disease patients naive to anti-TNF therapy. J. Clin. Gastroenterol. 2015;49:34–40.

    Article  PubMed  Google Scholar 

  19. De Gregorio M, Lee T, Krishnaprasad K et al. Higher anti-tumor necrosis factor-α levels correlate with improved radiologic outcomes in Crohn’s perianal fistulas. Clin. Gastroenterol. Hepatol. 2022;20:1306–1314.

    Article  PubMed  Google Scholar 

  20. Gu B, Venkatesh K, Williams AJ et al. Higher infliximab and adalimumab trough levels are associated with fistula healing in patients with fistulising perianal Crohn’s disease. World J. Gastroenterol. 2022;28:2597–2608.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Strik AS, Löwenberg M, Buskens CJ et al. Higher anti-TNF serum levels are associated with perianal fistula closure in Crohn’s disease patients. Scand. J. Gastroenterol. 2019;54:453–458.

    Article  CAS  PubMed  Google Scholar 

  22. Plevris N, Jenkinson PW, Arnott ID, Jones GR, Lees CW. Higher anti-tumor necrosis factor levels are associated with perianal fistula healing and fistula closure in Crohn’s disease. Eur. J. Gastroenterol. Hepatol. 2020;32:32–37.

    Article  CAS  PubMed  Google Scholar 

  23. Bouguen G, Siproudhis L, Gizard E et al. Long-term outcome of perianal fistulizing crohn’s disease treated with infliximab. Clin. Gastroenterol. Hepatol. 2013;11:975-981.e974.

    Article  CAS  PubMed  Google Scholar 

  24. Zhu M, Xu X, Feng Q et al. Effectiveness of infliximab on deep radiological remission in Chinese patients with perianal fistulizing Crohn’s disease. Dig. Dis. Sci. 2021;66:1658–1668.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This study was supported by the Leona M. and Harry B. Helmsley Charitable Trust.

Author information

Authors and Affiliations

  1. Division of Gastroenterology & Hepatology, Johns Hopkins University School of Medicine, 4940 Eastern Avenue, Baltimore, MD, 21224, USA

    Laura Maas, Ruiyi Gao, Reezwana Chowdhury, Mahesh Krishna, Mark Lazarev, Joanna Melia, Florin Selaru, Sowmya Sharma & Alyssa Parian

  2. Division of Digestive Diseases, Center for Inflammatory Bowel Diseases, Vatche & Tamar Manoukian, UCLA School of Medicine, Los Angeles, CA, USA

    Vivy Cusumano, Ellen Spartz & Berkeley Limketkai

Authors
  1. Laura Maas
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ruiyi Gao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Vivy Cusumano
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ellen Spartz
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Reezwana Chowdhury
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Mahesh Krishna
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Mark Lazarev
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Joanna Melia
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Florin Selaru
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Sowmya Sharma
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Berkeley Limketkai
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Alyssa Parian
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Laura Maas.

Ethics declarations

Conflict of interest

The authors of this study have no financial disclosures or conflicts of interest.

Ethical approval

This study was approved by the Institutional Review Boards of Johns Hopkins University and the University of California, Los Angeles (UCLA).

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Maas, L., Gao, R., Cusumano, V. et al. Superior Efficacy of Infliximab Versus Adalimumab for First-Line Treatment of Crohn’s Perianal Fistulae. Dig Dis Sci 68, 3994–4000 (2023). https://doi.org/10.1007/s10620-023-08060-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-023-08060-7

Keywords

Search

Navigation